IGC Pharma, Inc. (NASDAQ:IGC)

PRESS RELEASE

published on 11/14/2024 at 14:30, 1 year 10 months ago

IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer’s Pipeline
IGC Pharma, Inc. announces Q2 FY2025 financial results and strategic advancements including breakthroughs in Alzheimer's treatment pipeline. Revenue grows 42% to $412k. R&D expenses decrease 28%

Financial Results R&D Expenses Q2 FY2025 IGC Pharma Alzheimer's Treatment
BRIEF

published on 11/06/2024 at 14:35, 1 year 11 months ago

IGC Pharma met en avant des avancées stratégiques dans les thérapies contre la maladie d'Alzheimer et la perte de poids

Intelligence Artificielle Perte De Poids Agonistes Du GLP-1 IGC Pharma Traitement De La Maladie D'Alzheimer
BRIEF

published on 11/06/2024 at 14:35, 1 year 11 months ago

IGC Pharma Highlights Strategic Advances in Alzheimer's and Weight Loss Therapies

Weight Loss Artificial Intelligence GLP-1 Agonists IGC Pharma Alzheimer's Treatment
PRESS RELEASE

published on 11/06/2024 at 14:30, 1 year 11 months ago

IGC Pharma Announces Publication of IMS Spotlight Interview Highlighting Strategic Expansion in Alzheimer’s and Weight Loss Therapies
IGC Pharma, Inc. (NYSE American: IGC) announces a new interview with CEO Ram Mukunda discussing strategic expansion into metabolic and neurological markets, focusing on Alzheimer's and weight loss therapies, leveraging AI for diverse pipeline

Interview Neurodegenerative Disorders Metabolic Disorders IGC Pharma Ram Mukunda
BRIEF

published on 10/17/2024 at 14:35, 1 year 11 months ago

IGC Pharma étend son essai sur la maladie d'Alzheimer au Canada grâce à un partenariat avec Baycrest

IGC Pharma IGC-AD1 Essai Sur La Maladie D'Alzheimer Partenariat Baycrest Phase 2 Clinique
BRIEF

published on 10/17/2024 at 14:35, 1 year 11 months ago

IGC Pharma Expands Alzheimer's Trial to Canada with Baycrest Partnership

IGC Pharma Alzheimer's Trial IGC-AD1 Baycrest Partnership Phase 2 Clinical
PRESS RELEASE

published on 10/17/2024 at 14:30, 1 year 11 months ago

IGC Pharma Announces Patient Enrollment at Toronto's Baycrest in Phase 2 Trial Investigating IGC-AD1
IGC Pharma expands Phase 2 trial to Canada at Baycrest Academy for Research and Education in Toronto, Ontario, to investigate IGC-AD1 for treating agitation in Alzheimer's dementia

Phase 2 Trial Alzheimer's IGC Pharma Agitation Treatment Baycrest Academy
BRIEF

published on 10/03/2024 at 15:05, 2 years ago

IGC Pharma Secures Two Awards in NIH's AI PREPARE Challenge

AI Technology Healthcare Innovation IGC Pharma Alzheimer's Prediction NIH Challenge
BRIEF

published on 10/03/2024 at 15:05, 2 years ago

IGC Pharma remporte deux prix lors du concours AI PREPARE Challenge du NIH

Technologie De L'IA Innovation Dans Le Domaine De La Santé IGC Pharma Prédiction De La Maladie D'Alzheimer Défi Du NIH
PRESS RELEASE

published on 10/03/2024 at 15:00, 2 years ago

IGC Pharma Wins 2 Prizes in Phase 1 of National Institutes of Health's AI PREPARE Challenge
IGC Pharma, Inc. wins 2 awards in the PREPARE Challenge for Alzheimer's research with its MHAS entry. Recognition highlights leadership in AI for disease prediction

Artificial Intelligence Healthcare Innovation Alzheimer's Research IGC Pharma PREPARE Challenge

Published on 10/14/2026 at 11:00, 30 minutes ago

Meta Critical Minerals Appoints West Point Senior Advisor John Melkon to Strategic Advisory Board
Published on 10/14/2026 at 02:35, 8 hours 55 minutes ago

Prospect Ridge Announces First Tranche Closing of Critical Metals Flow-Through Unit Private Placement
Published on 10/14/2026 at 01:55, 9 hours 35 minutes ago

AI/ML Innovations Announces Completion of Share Issuance
Published on 10/14/2026 at 00:00, 11 hours 30 minutes ago

GGL Resources Corp. Announces Effective Date of Share Consolidation
Published on 10/13/2026 at 22:30, 13 hours ago

Navion Capital II Announces Termination of Letter of Intent

View all ACCESSWIRE

Published on 10/14/2026 at 11:12, 18 minutes ago

Finexity AG: FINEXITY Group signs Letter of Intent with OneCrowd Group – orderly continuity solution planned for issuers and investor base
Published on 10/14/2026 at 11:07, 23 minutes ago

Peter Schmid von Linstow appointed as new member of the Managing Board and CEO.
Published on 10/14/2026 at 11:05, 24 minutes ago

Make It Easy to Connect Your Switch to a Larger Screen -- HAILESI S123E Expands into Global Portable Monitor Markets across the UK, Germany, France and Australia, Achieving Top 5 Bestseller Status on Amazon
Published on 10/14/2026 at 10:41, 48 minutes ago

EQS-Adhoc: Finexity AG: FINEXITY Group signs Letter of Intent to take over OneCrowd-serviced issuances and investor base
Published on 10/14/2026 at 10:33, 56 minutes ago

EQS-Adhoc: KION GROUP AG: KION adjusts outlook for fiscal year 2026 and defers expected timing of mid-term targets beyond 2027

View all EQS

Published on 10/14/2026 at 10:39, 50 minutes ago

Number of shares and voting rights - September 2026 (In French only)
Published on 10/14/2026 at 10:39, 50 minutes ago

Nombre total d'actions et droits de vote - septembre 2026
Published on 10/14/2026 at 08:00, 3 hours 30 minutes ago

Kerlink Launches Wirnet™ iEdge Series
Published on 10/14/2026 at 08:00, 3 hours 30 minutes ago

Kerlink lance la gamme Wirnet™ iEdge
Published on 10/13/2026 at 17:45, 17 hours 44 minutes ago

ENGIE and CMA CGM join forces to invest in biomethane production in Le Havre

View all LES ECHOS COMFI WIRE

News